

Figure 1.





Figure 2.




Figure 3. Hazard ratios and 95% confidence intervals for primary and secondary outcomes per one standard deviation higher body mass index, waist hip ratio, waist circumference and waist to height ratio, respectively.




Table 1. Baseline characteristics for 11125 patients with anthropometric measures from the ADVANCE trial: overall and according to sex.

	Total n= 11125	Men n= 6397	Women n= 4728
Age, yr mean (SD)	66 (6)	66 (6)	66 (6)
Age when diabetes first diagnosed, yr — mean (SD)	58 (9)	58 (9)	58 (9)
Duration of diabetes, yr – mean (SD)	7.9 (6.4)	8.0 (6.5)	7.9 (6.2)
Age at completion of highest education, yr – median (Q1;Q3)	18 (7)	19 (7)	17 (7)
Anthropometric measures			
weight - median (Q1;Q3)	76 (66; 88)	81 (71; 92)	70 (61; 81)
WC, cm - Median (Q1;Q3)	98 (90; 106)	100 (92; 108)	95 (86; 103)
BMI, - median (Q1;Q3)	28 (25; 31)	27 (25; 30)	28 (25; 32)
WHR – median (Q1;Q3)	0.9 (0.9; 1.0)	1.0 (0.9; 1.0)	0.9 (0.8; 0.9)
WHtR - median (Q1;Q3)	0.59 (0.54; 0.64)	0.58 (0.54; 0.63)	0.60 (0.55; 0.65)
Previous vascular disease			
History of major macrovascular disease — no. /total no. (%)	3583/ 11125 (32)	2369/ 6397 (37)	1214/ 4728 (26)
Myocardial infarction — no. /total no. (%)	1329/ 11125 (12)	1005/ 6397 (16)	324/ 4728 (7)
Stroke — no. /total no. (%)	1021/ 11125 (9)	617/ 6397 (10)	404/ 4728 (9)
Blood-glucose control			
HbA1c level, % - median (Q1;Q3)	7.2 (6.5; 8.2)	7.2 (6.5; 8.1)	7.3 (6.5; 8.4)
Fasting blood glucose, mmol/liter – median (Q1;Q3)	7.9 (6.6; 9.7)	7.9 (6.6; 9.6)	8.0 (6.6; 9.9)
Other major risk factors			
Systolic blood pressure – mean (SD)	145 (22)	145 (21)	145 (22)

Diastolic blood pressure – mean (SD)	81 (11)	81 (11)	80 (11)
Serum cholesterol, mmol/liter – median (Q1;Q3)	5.1 (4.4; 5.9)	4.8 (4.2; 5.6)	5.5 (4.7; 6.3)
Low-density lipoprotein – median (Q1;Q3)	3.0 (2.4; 3.7)	2.8 (2.3; 3.5)	3.2 (2.6; 4.0)
High-density lipoprotein – median (Q1;Q3)	1.2 (1.0; 1.4)	1.1 (1.0; 1.4)	1.3 (1.1; 1.5)
Current smoking - no./total no. (%)	1549/ 11125 (14)	1115/ 6397 (17)	434/ 4728 (9)

Treatment at baseline

On antihypertensive treatment - no./ total no. (%)	7645/ 11125 (69)	4198/ 6397 (66)	3447/ 4728 (73)
Statin - no./ total no. (%)	3142/ 11125 (28)	2011/ 6397 (31)	1131/ 4728 (24)
Other lipid-modifying drug - no./ total no. (%)	933/ 11125 (8)	513/ 6397 (8)	420/ 4728 (9)
Aspirin - no./ total no. (%)	4889/ 11125 (44)	3056/ 6397 (48)	1833/ 4728 (39)
Other antiplatelet agent - no./ total no. (%)	504/ 11125 (5)	328/ 6397 (5)	176/ 4728 (4)
Oral anticoagulants - no./ total no. (%)	408/ 11125 (4)	255/ 6397 (4)	153/ 4728 (3)
Number of glucose lowering agents - median (Q1:Q3)	1.0 (1.0; 2.0)	1.0 (1.0; 2.0)	1.0 (1.0; 2.0)
Gliclazide (modified release) - no./ total no. (%)	865/ 11125 (8)	468/ 6397 (7)	397/ 4728 (8)
Other sulfonurea - no./ total no. (%)	7078/ 11124 (64)	4138/ 6397 (65)	2940/ 4727 (62)
Metformin - no./ total no. (%)	6747/ 11125 (61)	3847/ 6397 (60)	2900/ 4728 (61)
Thiazolidinedione - no./ total no. (%)	405/ 11125 (4)	265/ 6397 (4)	140/ 4728 (3)
Insulin - no./ total no. (%)	159/ 11125 (1)	66/ 6397 (1)	93/ 4728 (2)

Data are n (%) for categorical variables, mean (SD) for normally distributed continuous variables or median (Q1:Q3) for non-normally distributed continuous variables. Distribution was checked by use of the Anderson-Darling test.

WHR – waist hip ratio, BMI – body mass index, WC – waist circumference, WHtR – waist to height ratio

Table 2. Hazard ratios (95% confidence Interval) for major macrovascular event according to three waist to height ratio (WHtR) categories.

	WHtR <0.55	WHtR 0.55-<0.6	WHtR >=0.6	p for interaction
Participants - n (%)				
Men	1945 (30)	1904 (30)	2548 (40)	
Women	1225 (26)	1178 (25)	2325 (49)	
Asian	1967 (47.6)	1291 (31.2)	874 (21.2)	
Non-Asian	1203 (17.2)	1791 (25.6)	3999 (57.2)	
Age <66 years	1620 (30.6)	1413 (26.7)	2258 (42.7)	
Age >=66 years	1550 (26.6)	1669 (28.6)	2615 (44.8)	
All	3170 (28)	3082 (28)	4873 (44)	
Major macrovascular event				
Men	1 (reference)	1.22 (1.06-1.40)	1.39 (1.20-1.60)	0.7668
Women	1 (reference)	1.35 (1.11-1.65)	1.53 (1.27-1.84)	
Asian	1 (reference)	1.24 (1.07-1.44)	1.48 (1.25-1.74)	0.8045
Non-Asian	1 (reference)	1.30 (1.08-1.56)	1.45 (1.23-1.72)	
Age <66 years	1 (reference)	1.09 (0.92-1.31)	1.18 (1.01-1.39)	<0.0001
Age >=66 years	1 (reference)	1.25 (1.08-1.45)	1.27 (1.10-1.45)	
All	1 (reference)	1.27 (1.13-1.42)	1.44 (1.29-1.61)	

Adjusted for age, sex, current cigarette smoking, region, randomised blood pressure-lowering intervention and randomised glucose control intervention. P for trend was significant for all participants as well as sex, region and age subgroups. P for interaction between subgroups and WHtR categories are shown.